US FDA grants Orphan Drug and Fast Track Designation to elezanumab – a monoclonal antibody repulsive guidance molecule A (RGMa) inhibitor for treatment of spinal cord injury

RGMa is an inhibitor of axonal outgrowth and inhibits neuronal regeneration and functional recovery following central nervous system damage. Elezanumab is being investigated in phase 2 studies to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.

Source:

Biospace Inc.